Skip to main content
Top
Published in: Breast Cancer Research and Treatment 3/2018

01-06-2018 | Rebuttal Letter

Reply to Hollingsworth: does breast cancer metastasize in the clinical window between the mammogram and the mass?

Author: Steven A. Narod

Published in: Breast Cancer Research and Treatment | Issue 3/2018

Login to get access

Excerpt

In our recent review, we proposed the parallel theory of breast cancer which, succinctly put, states that if a breast cancer is going to metastasize it will have done so before it is clinically apparent [1]. When I read Alan Hollingsworth’s excellent book Mammography and Early Breast Cancer Detection: How Screening Saves Lives [2] I realized that our hypothesis was a revisiting of early Fisher theory. Hollingsworth summarizes Fisher theory on page 17 of his book [2]:
Fisher theory. Breast Cancer is either local or systemic at the time of discovery and progression from Biologic A to Biologic B does not occur during the clinical window. Thus, variation in the manner of local control are unlikely to have substantial impact on survival. Note: Unlike Halsted theory, there are no arrows in this schematic.
Literature
2.
go back to reference Hollingsworth AB (2016) Mammography and early breast cancer detection: how screening saves lives. McFarland & Company Inc, North Carolina Hollingsworth AB (2016) Mammography and early breast cancer detection: how screening saves lives. McFarland & Company Inc, North Carolina
4.
go back to reference Fisher B (1985) The revolution in breast cancer surgery: science or anecdotalism? World J Surg 9:655–666CrossRefPubMed Fisher B (1985) The revolution in breast cancer surgery: science or anecdotalism? World J Surg 9:655–666CrossRefPubMed
5.
go back to reference Fisher B, Anderson SJ (2010) The breast cancer alternative hypothesis: is there evidence to justify replacing it? J Clin Oncol 28:366–374CrossRefPubMed Fisher B, Anderson SJ (2010) The breast cancer alternative hypothesis: is there evidence to justify replacing it? J Clin Oncol 28:366–374CrossRefPubMed
6.
go back to reference Tabár L, Vitak B, Chen TH et al (2011) Swedish two-county trial: impact of mammographic screening on breast cancer mortality during 3 decades. Radiology 260:658–663CrossRefPubMed Tabár L, Vitak B, Chen TH et al (2011) Swedish two-county trial: impact of mammographic screening on breast cancer mortality during 3 decades. Radiology 260:658–663CrossRefPubMed
7.
8.
go back to reference Berg WA, Zhang Z, Lehrer D et al (2012) Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. JAMA 307:1394–1404CrossRefPubMedPubMedCentral Berg WA, Zhang Z, Lehrer D et al (2012) Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. JAMA 307:1394–1404CrossRefPubMedPubMedCentral
9.
go back to reference Lång K, Andersson I, Rosso A, Tingberg A, Timberg P, Zackrisson S (2016) Performance of one-view breast tomosynthesis as a stand-alone breast cancer screening modality: results from the Malmö Breast Tomosynthesis Screening Trial, a population-based study. Eur Radiol 26:184–190CrossRefPubMed Lång K, Andersson I, Rosso A, Tingberg A, Timberg P, Zackrisson S (2016) Performance of one-view breast tomosynthesis as a stand-alone breast cancer screening modality: results from the Malmö Breast Tomosynthesis Screening Trial, a population-based study. Eur Radiol 26:184–190CrossRefPubMed
10.
go back to reference Kuhl CK, Strobel K, Bieling H, Leutner C, Schild HH, Schrading S (2017) Supplemental breast mr imaging screening of women with average risk of breast cancer. Radiology 283:361–370CrossRefPubMed Kuhl CK, Strobel K, Bieling H, Leutner C, Schild HH, Schrading S (2017) Supplemental breast mr imaging screening of women with average risk of breast cancer. Radiology 283:361–370CrossRefPubMed
11.
go back to reference American Cancer Society (2017) Breast cancer facts & figures 2017–2018. American Cancer Society Inc, Atlanta American Cancer Society (2017) Breast cancer facts & figures 2017–2018. American Cancer Society Inc, Atlanta
Metadata
Title
Reply to Hollingsworth: does breast cancer metastasize in the clinical window between the mammogram and the mass?
Author
Steven A. Narod
Publication date
01-06-2018
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2018
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-018-4739-5

Other articles of this Issue 3/2018

Breast Cancer Research and Treatment 3/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine